GlassScriptPhysician profile
Issac M Esseesse
NPI 1194820019
$1,706.79
in general payments reported to CMS, 2019-2025
14 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $146 · 2024: $791 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $916.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $178.55 | 2019 | |
| Incyte Corporation | $173.46 | 2019 | |
| Pharmaessentia USA Corporation | $125.00 | 2025 | Besremi |
| Genmab U.S., INC. | $121.92 | 2024 | Epkinly |
| Sobi, INC | $121.03 | 2024 | |
| Janssen Biotech, INC. | $121.00 | 2024 | Rybrevant |
| Blueprint Medicines Corporation | $120.83 | 2024 | Ayvakit |
| Seagen INC. | $118.11 | 2020 | |
| Emd Serono, INC. | $117.44 | 2019 | |
| Merck Sharp & Dohme LLC | $116.93 | 2019 | |
| Beigene USA, INC. | $115.34 | 2020-2024 | Brukinsa |
| Stemline Therapeutics INC. | $110.01 | 2024 | Orserdu |
| Aveo Pharmaceuticals, INC. | $108.84 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Issac Esseesse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.